Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats

European Journal of Vascular and Endovascular Surgery

Volumn 23, Issue 3, 2002, Pages 234-240

  Waller, J R ^a,b   Murphy, G J ^a   Bicknell, G R ^a   Sandford, R ^a   Margolin, S B ^a   Nicholson, M L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

Author keywords

Extracellular matrix; Intimal hyperplasia; Metalloproteinase

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 3; GELATINASE A; GELATINASE B; METALLOPROTEINASE; PIRFENIDONE; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; DOSE RESPONSE; EXPLANT; EXTRACELLULAR MATRIX; INTIMA; MALE; MIGRATION; MORPHOLOGY; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; STATISTICAL ANALYSIS; STEREOMETRY; ANIMAL; CAROTID ARTERY; CAROTID ARTERY INJURY; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION; GROWTH, DEVELOPMENT AND AGING; INJURY; TIME;

ANGIOPLASTY, BALLOON; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAROTID ARTERIES; CAROTID ARTERY INJURIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; GENE EXPRESSION; MALE; METALLOENDOPEPTIDASES; PYRIDONES; RATS; TIME FACTORS; TUNICA INTIMA;

EID: 0036514365     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1053/ejvs.2001.1574     Document Type: Article

References (38)

1. WANG AY, BOBREYSHEV YV, CHERIAN SM et al. Structural features of cell death in atherosclerotic lesions affecting long-term aortocoronary saphenous vein bypass grafts. J Submicroscopic Cytol Path 1999; 31(3): 423-432.
2. RODRIGUEZ A, BERNADI V, NAVIA J et al. Argentine Randomised Study: Coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease: (ERACI II): 30-day and one-year follow-up results: ERACI II Investigators. J Am Coll Cardiol 2001; 37(1): 51-58.
3. ARANDA JM, HILL J. Cardiac transplant vasculopathy. Chest 2000; 118(6): 1792-1800.
4. CAMPEAU L, ENJALBERT M, LESPERANCE J et al. Atherosclerosis and late closure of saphenous vein grafts: sequential angiographic studies 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation 1983; 68 (suppl II): II-1-II-7.
5. SCHWARTZ SM, DEBLOIS D, O'BRIEN ERM. The intima: Soil for atherosclerosis and restenosis. Circulation Res 1995; 77(3): 445-465.
6. JAWIEN A, BOWEN-POPE DF, LINDNER V, SCHWARTZ SM, CLOWES AW. Platelet-derived growth factor promotes smooth muscle cell migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992; 89: 507-511.
7. FERNS GAA, RAINES EW, SPRUGEL KH et al. Inhibition of neointimal smooth muscle cell accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-1132.
8. LINDNER V, REIDY MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic firoblast growth factor. Proc Natl Acad Sci USA 1991; 88: 3739-3743.
9. OLSON NE, CHAO S, LINDNER V, REIDY MA. Intima smooth muscle cell proliferation after balloon catheter injury: the role of basic fibroblast factor. Am J Pathol 1992; 140: 1017-1023.
10. MAJESKY MW, LINDNER V, TWARDZIK DR, SCHWARTZ SM, REIDY MA. Production of transforming growth factor beta-1 during repair of arterial injury. J Clin Invest 1991; 88: 904-910.
11. THYBERG J, HEDIN U, SJOLUND M, PALMBERG L, BOTTGER BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 1990; 10: 966-990.
12. HEDIN U, SJOLUND M, HULTGARDH-NILSSON A, THYBERG J. Changes in expression and organisation of smooth muscle cell specific alpha-actin during fibronectin-mediated modulation of arterial smooth muscle cell phenotype. Differentiation 1990; 44: 222-231.
13. SATO H, TAKINO T, OKADO Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65.
14. BENDECK MP, ZEMPO N, CLOWES A, GALARDY R, REIDY MA. Smooth muscle cell migration and metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75: 539-545.
15. WEBB KE, HENNEY AM, ANGLIN S, HUMPHRIES SE, MCEWAN JR. Expression of matrix metalloproteinase and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arteriosclerosis, Thrombosis & Vascular Biology 1997; 17(9): 1837-1844.
16. IYER SN, GURUJEYALAKSHMI G, GIRI SN. Effects of Pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of fibrosis. J Pharmacol Exp Therap 1999; 289: 211-218.
17. LEE BS, MARGOLIN SB, NOWAK RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin End Met 1998; 83(1): 219-223.
18. SHIMIZA T, FUKAGAWA M, KURODA T et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney International 1997; 63: S239-S243.
19. CLOWES AW, CLOWES MM, REIDY MA. Kinetics of cellular proliferation after arterial injury, I: smooth muscle cell growth in the absence of endothelium. Lab Investigation 1983; 49: 327-333.
20. HALL LL, BICKNELL GR, PRIMROSE L et al. Reproducibility in the quantification of mRNA levels by RT-PCR-ELISA and RT competitive-PCR-ELISA. Biotechniques 1998; 24: 652-658.
21. WILLS A, THOMPSON MM, CROWTHER M et al. Elastase-induced matrix degradation in arterial organ cultures. An in vitro of aneurysmal disease. J Vasc Surg 1996; 24: 667-679.
22. BRADFORD MM. Rapid and sensitive method for quantification of microgram quantities of protein utilising principle of protein-dye binding. Annual Biochem 1876; 72: 248-254.
23. TADA T, REIDY MA. Endothelial regeneration, IX: arterial injury followed by rapid endothelial repair induces smooth muscle cell proliferation but not intimal thickening. Am J Path 1987; 129: 429-433.
24. ZEMPO N, KENAGY RD, AU YP et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg 1994; 20: 209-217.
25. DOLLERY C, MCEWAN J, HENNEY A. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-868.
26. SOUTHGATE KM, DAVIES M, BOOTH RFG, NEWBY AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J 1992; 288: 93-99.
27. BENDECK MP, IRVIN C, REIDY MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not intimal thickening after arterial injury. Circ Res 1996; 78: 38-43.
28. MURPHY G, WILLNEBROCK F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995; 248: 496-510.
29. CLOWES AW, CLOWES MM. Kinetics of cellular proliferation after arterial injury, IV: heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res 1986; 58: 839-845.
30. MONTESANO R, PEPPER MS, MOHLE-STEINLEIN U et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour of endothelial cells expressing the middle T oncogene. Cell 1990; 62: 435-445.
31. CLOWES MM, LYNCH CM, MILLER A et al. Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally induced human genes. J Clin Invest 1994; 93: 644-651.
32. SCHWARTZ RS, HOLMES DR, TOPOL EJ. The restenosis paradigm revisited. An alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1284-1293.
33. DOSANJH AK, WAN B, THRONDSET W, SHERWOOD S, MORRIS RE. Pirfinedone: a novel anti-fibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplantation Proc 1998; 30 (5): 1910-1911.
34. SCHIMIZU T, FUKAGAWA M, KURODA T et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int 1997; 52: S-239-243.
35. BYUNG-SEOK L, MARGOLIN SB, NOWAK RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinology Metabolism 1998; 83: 219-223.
36. NICOD LP. Pirfenidone in idiopathic pulmonary fibrosis. Lancet 1999; 354(9175): 268-269.
37. NABEL EG, SHUM L, POMPILI VJ et al. Direct transfer of transforming growth factor beta-1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad USA 1993; 90: 10759-10763.
38. IYER SN, GURUJEYALAKSHMI G, GIRI SN. Effect on pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of fibrosis. J Pharm Esp Therap 1999; 291: 367-373.